MedTrace Logo

Desloratadine in Patients With Ulcerative Colitis

NCT07333716 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-01-29

No results posted yet for this study

Summary

The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.

Conditions

Interventions

DRUG

Desloratadine

mesalamine 1000 mg three times daily plus desloratadine 5 mg once daily for 3 months.

DRUG

mesalamine

mesalamine 1000 mg three times daily for 3 months

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Romisaa R Abd Alnapy · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-26
Primary Completion
2027-02-28
Completion
2027-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07333716 on ClinicalTrials.gov